Global Coronary Drug

Coronary Drug Comprehensive Study by Type (Durable Polymer Drug-eluting Stents, Bioabsorbable Polymer Drug-eluting Stent, Other), Application (Coronary Heart Disease, Clinical), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) Players and Region - Global Market Outlook to 2026

Coronary Drug Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Coronary Drug Market Scope
According to Centres for Disease Control and Prevention, the U.S., about 655,000 Americans die from heart disease each year that’s 1 in every 4 deaths. It is a leading cause of death for men, women, and people of most racial and ethnic groups and one person dies every 36 seconds in the United States. Heart disease is a range of conditions that affect heart include blood vessel diseases, such as coronary artery disease; heart rhythm problems (arrhythmias), congenital heart defects and others.

The Coronary Drug market study is segmented by Type (Durable Polymer Drug-eluting Stents, Bioabsorbable Polymer Drug-eluting Stent and Other), by Application (Coronary Heart Disease and Clinical) and major geographies with country level break-up.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Coronary Drug market throughout the predicted period.

Boston Scientific (United States), Cordis (United States), Abbott (United States), Advantec Vascular (United States), B.Braun Melsengen AG (Germany), Biotronik (Germany) and Medtronic (United States) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Coronary Drug market by Type, Application and Region.

On the basis of geography, the market of Coronary Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Market Trend
  • Increasing Number of Online Pharmacies
  • Increasing Investment in Research and Development

Market Drivers
  • Increased Prevalence of Cardiovascular Diseases
  • Increased Number of Diagnostic Centres and Hospitals
  • Increased Awareness and Innovation of New Drugs

Opportunities
  • Growth in the Healthcare Industry Worldwide
  • Huge Investment by Major Players
  • Growing Demand for Advanced and Effective Drugs

Restraints
  • Side Effects of the Drugs

Challenges
  • Stringent Government Rules and Regulations


Key Target Audience
Coronary Drug Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies, Research Professionals and End-users

Report Objectives / Segmentation Covered

By Type
  • Durable Polymer Drug-eluting Stents
  • Bioabsorbable Polymer Drug-eluting Stent
  • Other
By Application
  • Coronary Heart Disease
  • Clinical
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Cardiovascular Diseases
      • 3.2.2. Increased Number of Diagnostic Centres and Hospitals
      • 3.2.3. Increased Awareness and Innovation of New Drugs
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increasing Number of Online Pharmacies
      • 3.4.2. Increasing Investment in Research and Development
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Coronary Drug, by Type, Application, Distribution Channel and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Coronary Drug (Value)
      • 5.2.1. Global Coronary Drug by: Type (Value)
        • 5.2.1.1. Durable Polymer Drug-eluting Stents
        • 5.2.1.2. Bioabsorbable Polymer Drug-eluting Stent
        • 5.2.1.3. Other
      • 5.2.2. Global Coronary Drug by: Application (Value)
        • 5.2.2.1. Coronary Heart Disease
        • 5.2.2.2. Clinical
      • 5.2.3. Global Coronary Drug by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online Pharmacies
        • 5.2.3.4. Others
      • 5.2.4. Global Coronary Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Coronary Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Boston Scientific (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Cordis (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Abbott (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Advantec Vascular (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. B.Braun Melsengen AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Biotronik (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Medtronic (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Coronary Drug Sale, by Type, Application, Distribution Channel and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Coronary Drug (Value)
      • 7.2.1. Global Coronary Drug by: Type (Value)
        • 7.2.1.1. Durable Polymer Drug-eluting Stents
        • 7.2.1.2. Bioabsorbable Polymer Drug-eluting Stent
        • 7.2.1.3. Other
      • 7.2.2. Global Coronary Drug by: Application (Value)
        • 7.2.2.1. Coronary Heart Disease
        • 7.2.2.2. Clinical
      • 7.2.3. Global Coronary Drug by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online Pharmacies
        • 7.2.3.4. Others
      • 7.2.4. Global Coronary Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Coronary Drug: by Type(USD Million)
  • Table 2. Coronary Drug Durable Polymer Drug-eluting Stents , by Region USD Million (2015-2020)
  • Table 3. Coronary Drug Bioabsorbable Polymer Drug-eluting Stent , by Region USD Million (2015-2020)
  • Table 4. Coronary Drug Other , by Region USD Million (2015-2020)
  • Table 5. Coronary Drug: by Application(USD Million)
  • Table 6. Coronary Drug Coronary Heart Disease , by Region USD Million (2015-2020)
  • Table 7. Coronary Drug Clinical , by Region USD Million (2015-2020)
  • Table 8. Coronary Drug: by Distribution Channel(USD Million)
  • Table 9. Coronary Drug Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 10. Coronary Drug Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 11. Coronary Drug Online Pharmacies , by Region USD Million (2015-2020)
  • Table 12. Coronary Drug Others , by Region USD Million (2015-2020)
  • Table 13. South America Coronary Drug, by Country USD Million (2015-2020)
  • Table 14. South America Coronary Drug, by Type USD Million (2015-2020)
  • Table 15. South America Coronary Drug, by Application USD Million (2015-2020)
  • Table 16. South America Coronary Drug, by Distribution Channel USD Million (2015-2020)
  • Table 17. Brazil Coronary Drug, by Type USD Million (2015-2020)
  • Table 18. Brazil Coronary Drug, by Application USD Million (2015-2020)
  • Table 19. Brazil Coronary Drug, by Distribution Channel USD Million (2015-2020)
  • Table 20. Argentina Coronary Drug, by Type USD Million (2015-2020)
  • Table 21. Argentina Coronary Drug, by Application USD Million (2015-2020)
  • Table 22. Argentina Coronary Drug, by Distribution Channel USD Million (2015-2020)
  • Table 23. Rest of South America Coronary Drug, by Type USD Million (2015-2020)
  • Table 24. Rest of South America Coronary Drug, by Application USD Million (2015-2020)
  • Table 25. Rest of South America Coronary Drug, by Distribution Channel USD Million (2015-2020)
  • Table 26. Asia Pacific Coronary Drug, by Country USD Million (2015-2020)
  • Table 27. Asia Pacific Coronary Drug, by Type USD Million (2015-2020)
  • Table 28. Asia Pacific Coronary Drug, by Application USD Million (2015-2020)
  • Table 29. Asia Pacific Coronary Drug, by Distribution Channel USD Million (2015-2020)
  • Table 30. China Coronary Drug, by Type USD Million (2015-2020)
  • Table 31. China Coronary Drug, by Application USD Million (2015-2020)
  • Table 32. China Coronary Drug, by Distribution Channel USD Million (2015-2020)
  • Table 33. Japan Coronary Drug, by Type USD Million (2015-2020)
  • Table 34. Japan Coronary Drug, by Application USD Million (2015-2020)
  • Table 35. Japan Coronary Drug, by Distribution Channel USD Million (2015-2020)
  • Table 36. India Coronary Drug, by Type USD Million (2015-2020)
  • Table 37. India Coronary Drug, by Application USD Million (2015-2020)
  • Table 38. India Coronary Drug, by Distribution Channel USD Million (2015-2020)
  • Table 39. South Korea Coronary Drug, by Type USD Million (2015-2020)
  • Table 40. South Korea Coronary Drug, by Application USD Million (2015-2020)
  • Table 41. South Korea Coronary Drug, by Distribution Channel USD Million (2015-2020)
  • Table 42. Taiwan Coronary Drug, by Type USD Million (2015-2020)
  • Table 43. Taiwan Coronary Drug, by Application USD Million (2015-2020)
  • Table 44. Taiwan Coronary Drug, by Distribution Channel USD Million (2015-2020)
  • Table 45. Australia Coronary Drug, by Type USD Million (2015-2020)
  • Table 46. Australia Coronary Drug, by Application USD Million (2015-2020)
  • Table 47. Australia Coronary Drug, by Distribution Channel USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Coronary Drug, by Type USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Coronary Drug, by Application USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Coronary Drug, by Distribution Channel USD Million (2015-2020)
  • Table 51. Europe Coronary Drug, by Country USD Million (2015-2020)
  • Table 52. Europe Coronary Drug, by Type USD Million (2015-2020)
  • Table 53. Europe Coronary Drug, by Application USD Million (2015-2020)
  • Table 54. Europe Coronary Drug, by Distribution Channel USD Million (2015-2020)
  • Table 55. Germany Coronary Drug, by Type USD Million (2015-2020)
  • Table 56. Germany Coronary Drug, by Application USD Million (2015-2020)
  • Table 57. Germany Coronary Drug, by Distribution Channel USD Million (2015-2020)
  • Table 58. France Coronary Drug, by Type USD Million (2015-2020)
  • Table 59. France Coronary Drug, by Application USD Million (2015-2020)
  • Table 60. France Coronary Drug, by Distribution Channel USD Million (2015-2020)
  • Table 61. Italy Coronary Drug, by Type USD Million (2015-2020)
  • Table 62. Italy Coronary Drug, by Application USD Million (2015-2020)
  • Table 63. Italy Coronary Drug, by Distribution Channel USD Million (2015-2020)
  • Table 64. United Kingdom Coronary Drug, by Type USD Million (2015-2020)
  • Table 65. United Kingdom Coronary Drug, by Application USD Million (2015-2020)
  • Table 66. United Kingdom Coronary Drug, by Distribution Channel USD Million (2015-2020)
  • Table 67. Netherlands Coronary Drug, by Type USD Million (2015-2020)
  • Table 68. Netherlands Coronary Drug, by Application USD Million (2015-2020)
  • Table 69. Netherlands Coronary Drug, by Distribution Channel USD Million (2015-2020)
  • Table 70. Rest of Europe Coronary Drug, by Type USD Million (2015-2020)
  • Table 71. Rest of Europe Coronary Drug, by Application USD Million (2015-2020)
  • Table 72. Rest of Europe Coronary Drug, by Distribution Channel USD Million (2015-2020)
  • Table 73. MEA Coronary Drug, by Country USD Million (2015-2020)
  • Table 74. MEA Coronary Drug, by Type USD Million (2015-2020)
  • Table 75. MEA Coronary Drug, by Application USD Million (2015-2020)
  • Table 76. MEA Coronary Drug, by Distribution Channel USD Million (2015-2020)
  • Table 77. Middle East Coronary Drug, by Type USD Million (2015-2020)
  • Table 78. Middle East Coronary Drug, by Application USD Million (2015-2020)
  • Table 79. Middle East Coronary Drug, by Distribution Channel USD Million (2015-2020)
  • Table 80. Africa Coronary Drug, by Type USD Million (2015-2020)
  • Table 81. Africa Coronary Drug, by Application USD Million (2015-2020)
  • Table 82. Africa Coronary Drug, by Distribution Channel USD Million (2015-2020)
  • Table 83. North America Coronary Drug, by Country USD Million (2015-2020)
  • Table 84. North America Coronary Drug, by Type USD Million (2015-2020)
  • Table 85. North America Coronary Drug, by Application USD Million (2015-2020)
  • Table 86. North America Coronary Drug, by Distribution Channel USD Million (2015-2020)
  • Table 87. United States Coronary Drug, by Type USD Million (2015-2020)
  • Table 88. United States Coronary Drug, by Application USD Million (2015-2020)
  • Table 89. United States Coronary Drug, by Distribution Channel USD Million (2015-2020)
  • Table 90. Canada Coronary Drug, by Type USD Million (2015-2020)
  • Table 91. Canada Coronary Drug, by Application USD Million (2015-2020)
  • Table 92. Canada Coronary Drug, by Distribution Channel USD Million (2015-2020)
  • Table 93. Mexico Coronary Drug, by Type USD Million (2015-2020)
  • Table 94. Mexico Coronary Drug, by Application USD Million (2015-2020)
  • Table 95. Mexico Coronary Drug, by Distribution Channel USD Million (2015-2020)
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Coronary Drug: by Type(USD Million)
  • Table 104. Coronary Drug Durable Polymer Drug-eluting Stents , by Region USD Million (2021-2026)
  • Table 105. Coronary Drug Bioabsorbable Polymer Drug-eluting Stent , by Region USD Million (2021-2026)
  • Table 106. Coronary Drug Other , by Region USD Million (2021-2026)
  • Table 107. Coronary Drug: by Application(USD Million)
  • Table 108. Coronary Drug Coronary Heart Disease , by Region USD Million (2021-2026)
  • Table 109. Coronary Drug Clinical , by Region USD Million (2021-2026)
  • Table 110. Coronary Drug: by Distribution Channel(USD Million)
  • Table 111. Coronary Drug Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 112. Coronary Drug Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 113. Coronary Drug Online Pharmacies , by Region USD Million (2021-2026)
  • Table 114. Coronary Drug Others , by Region USD Million (2021-2026)
  • Table 115. South America Coronary Drug, by Country USD Million (2021-2026)
  • Table 116. South America Coronary Drug, by Type USD Million (2021-2026)
  • Table 117. South America Coronary Drug, by Application USD Million (2021-2026)
  • Table 118. South America Coronary Drug, by Distribution Channel USD Million (2021-2026)
  • Table 119. Brazil Coronary Drug, by Type USD Million (2021-2026)
  • Table 120. Brazil Coronary Drug, by Application USD Million (2021-2026)
  • Table 121. Brazil Coronary Drug, by Distribution Channel USD Million (2021-2026)
  • Table 122. Argentina Coronary Drug, by Type USD Million (2021-2026)
  • Table 123. Argentina Coronary Drug, by Application USD Million (2021-2026)
  • Table 124. Argentina Coronary Drug, by Distribution Channel USD Million (2021-2026)
  • Table 125. Rest of South America Coronary Drug, by Type USD Million (2021-2026)
  • Table 126. Rest of South America Coronary Drug, by Application USD Million (2021-2026)
  • Table 127. Rest of South America Coronary Drug, by Distribution Channel USD Million (2021-2026)
  • Table 128. Asia Pacific Coronary Drug, by Country USD Million (2021-2026)
  • Table 129. Asia Pacific Coronary Drug, by Type USD Million (2021-2026)
  • Table 130. Asia Pacific Coronary Drug, by Application USD Million (2021-2026)
  • Table 131. Asia Pacific Coronary Drug, by Distribution Channel USD Million (2021-2026)
  • Table 132. China Coronary Drug, by Type USD Million (2021-2026)
  • Table 133. China Coronary Drug, by Application USD Million (2021-2026)
  • Table 134. China Coronary Drug, by Distribution Channel USD Million (2021-2026)
  • Table 135. Japan Coronary Drug, by Type USD Million (2021-2026)
  • Table 136. Japan Coronary Drug, by Application USD Million (2021-2026)
  • Table 137. Japan Coronary Drug, by Distribution Channel USD Million (2021-2026)
  • Table 138. India Coronary Drug, by Type USD Million (2021-2026)
  • Table 139. India Coronary Drug, by Application USD Million (2021-2026)
  • Table 140. India Coronary Drug, by Distribution Channel USD Million (2021-2026)
  • Table 141. South Korea Coronary Drug, by Type USD Million (2021-2026)
  • Table 142. South Korea Coronary Drug, by Application USD Million (2021-2026)
  • Table 143. South Korea Coronary Drug, by Distribution Channel USD Million (2021-2026)
  • Table 144. Taiwan Coronary Drug, by Type USD Million (2021-2026)
  • Table 145. Taiwan Coronary Drug, by Application USD Million (2021-2026)
  • Table 146. Taiwan Coronary Drug, by Distribution Channel USD Million (2021-2026)
  • Table 147. Australia Coronary Drug, by Type USD Million (2021-2026)
  • Table 148. Australia Coronary Drug, by Application USD Million (2021-2026)
  • Table 149. Australia Coronary Drug, by Distribution Channel USD Million (2021-2026)
  • Table 150. Rest of Asia-Pacific Coronary Drug, by Type USD Million (2021-2026)
  • Table 151. Rest of Asia-Pacific Coronary Drug, by Application USD Million (2021-2026)
  • Table 152. Rest of Asia-Pacific Coronary Drug, by Distribution Channel USD Million (2021-2026)
  • Table 153. Europe Coronary Drug, by Country USD Million (2021-2026)
  • Table 154. Europe Coronary Drug, by Type USD Million (2021-2026)
  • Table 155. Europe Coronary Drug, by Application USD Million (2021-2026)
  • Table 156. Europe Coronary Drug, by Distribution Channel USD Million (2021-2026)
  • Table 157. Germany Coronary Drug, by Type USD Million (2021-2026)
  • Table 158. Germany Coronary Drug, by Application USD Million (2021-2026)
  • Table 159. Germany Coronary Drug, by Distribution Channel USD Million (2021-2026)
  • Table 160. France Coronary Drug, by Type USD Million (2021-2026)
  • Table 161. France Coronary Drug, by Application USD Million (2021-2026)
  • Table 162. France Coronary Drug, by Distribution Channel USD Million (2021-2026)
  • Table 163. Italy Coronary Drug, by Type USD Million (2021-2026)
  • Table 164. Italy Coronary Drug, by Application USD Million (2021-2026)
  • Table 165. Italy Coronary Drug, by Distribution Channel USD Million (2021-2026)
  • Table 166. United Kingdom Coronary Drug, by Type USD Million (2021-2026)
  • Table 167. United Kingdom Coronary Drug, by Application USD Million (2021-2026)
  • Table 168. United Kingdom Coronary Drug, by Distribution Channel USD Million (2021-2026)
  • Table 169. Netherlands Coronary Drug, by Type USD Million (2021-2026)
  • Table 170. Netherlands Coronary Drug, by Application USD Million (2021-2026)
  • Table 171. Netherlands Coronary Drug, by Distribution Channel USD Million (2021-2026)
  • Table 172. Rest of Europe Coronary Drug, by Type USD Million (2021-2026)
  • Table 173. Rest of Europe Coronary Drug, by Application USD Million (2021-2026)
  • Table 174. Rest of Europe Coronary Drug, by Distribution Channel USD Million (2021-2026)
  • Table 175. MEA Coronary Drug, by Country USD Million (2021-2026)
  • Table 176. MEA Coronary Drug, by Type USD Million (2021-2026)
  • Table 177. MEA Coronary Drug, by Application USD Million (2021-2026)
  • Table 178. MEA Coronary Drug, by Distribution Channel USD Million (2021-2026)
  • Table 179. Middle East Coronary Drug, by Type USD Million (2021-2026)
  • Table 180. Middle East Coronary Drug, by Application USD Million (2021-2026)
  • Table 181. Middle East Coronary Drug, by Distribution Channel USD Million (2021-2026)
  • Table 182. Africa Coronary Drug, by Type USD Million (2021-2026)
  • Table 183. Africa Coronary Drug, by Application USD Million (2021-2026)
  • Table 184. Africa Coronary Drug, by Distribution Channel USD Million (2021-2026)
  • Table 185. North America Coronary Drug, by Country USD Million (2021-2026)
  • Table 186. North America Coronary Drug, by Type USD Million (2021-2026)
  • Table 187. North America Coronary Drug, by Application USD Million (2021-2026)
  • Table 188. North America Coronary Drug, by Distribution Channel USD Million (2021-2026)
  • Table 189. United States Coronary Drug, by Type USD Million (2021-2026)
  • Table 190. United States Coronary Drug, by Application USD Million (2021-2026)
  • Table 191. United States Coronary Drug, by Distribution Channel USD Million (2021-2026)
  • Table 192. Canada Coronary Drug, by Type USD Million (2021-2026)
  • Table 193. Canada Coronary Drug, by Application USD Million (2021-2026)
  • Table 194. Canada Coronary Drug, by Distribution Channel USD Million (2021-2026)
  • Table 195. Mexico Coronary Drug, by Type USD Million (2021-2026)
  • Table 196. Mexico Coronary Drug, by Application USD Million (2021-2026)
  • Table 197. Mexico Coronary Drug, by Distribution Channel USD Million (2021-2026)
  • Table 198. Research Programs/Design for This Report
  • Table 199. Key Data Information from Secondary Sources
  • Table 200. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Coronary Drug: by Type USD Million (2015-2020)
  • Figure 5. Global Coronary Drug: by Application USD Million (2015-2020)
  • Figure 6. Global Coronary Drug: by Distribution Channel USD Million (2015-2020)
  • Figure 7. South America Coronary Drug Share (%), by Country
  • Figure 8. Asia Pacific Coronary Drug Share (%), by Country
  • Figure 9. Europe Coronary Drug Share (%), by Country
  • Figure 10. MEA Coronary Drug Share (%), by Country
  • Figure 11. North America Coronary Drug Share (%), by Country
  • Figure 12. Global Coronary Drug share by Players 2020 (%)
  • Figure 13. Global Coronary Drug share by Players (Top 3) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Boston Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 16. Boston Scientific (United States) Revenue: by Geography 2020
  • Figure 17. Cordis (United States) Revenue, Net Income and Gross profit
  • Figure 18. Cordis (United States) Revenue: by Geography 2020
  • Figure 19. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 20. Abbott (United States) Revenue: by Geography 2020
  • Figure 21. Advantec Vascular (United States) Revenue, Net Income and Gross profit
  • Figure 22. Advantec Vascular (United States) Revenue: by Geography 2020
  • Figure 23. B.Braun Melsengen AG (Germany) Revenue, Net Income and Gross profit
  • Figure 24. B.Braun Melsengen AG (Germany) Revenue: by Geography 2020
  • Figure 25. Biotronik (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Biotronik (Germany) Revenue: by Geography 2020
  • Figure 27. Medtronic (United States) Revenue, Net Income and Gross profit
  • Figure 28. Medtronic (United States) Revenue: by Geography 2020
  • Figure 29. Global Coronary Drug: by Type USD Million (2021-2026)
  • Figure 30. Global Coronary Drug: by Application USD Million (2021-2026)
  • Figure 31. Global Coronary Drug: by Distribution Channel USD Million (2021-2026)
  • Figure 32. South America Coronary Drug Share (%), by Country
  • Figure 33. Asia Pacific Coronary Drug Share (%), by Country
  • Figure 34. Europe Coronary Drug Share (%), by Country
  • Figure 35. MEA Coronary Drug Share (%), by Country
  • Figure 36. North America Coronary Drug Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Boston Scientific (United States)
  • Cordis (United States)
  • Abbott (United States)
  • Advantec Vascular (United States)
  • B.Braun Melsengen AG (Germany)
  • Biotronik (Germany)
  • Medtronic (United States)
Select User Access Type

Key Highlights of Report


Apr 2021 201 Pages 52 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Coronary Drug Quantitative research analysis
Global Coronary Drug Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Know More About Global Coronary Drug Report?

Have a Query? Click Here

Other Related Reports

Pentazocine Comprehensive Study by Application (Postoperative pain, Chronic Pain, Obstetrics, Renal and biliary colic, Myocardial infarction, Intravenous anaesthesia and premedication, Others), Patie...
$ 3750
Thrombolytic Drug Comprehensive Study by Type (Tissue plasminogen activator (tPA), Streptokinase (SK), Urokinase (UK)), Application (Drug Treatment, Surgical Treatment, Other Treatment), Fibrin (Fibr...
$ 3650
Livestock Dewormers Comprehensive Study by Mode of Administration (Topical, Injection, Oral), End Users (Veterinary Hospitals, Veterinary Clinics, Others), Animal Type (Cattle, Swine, Poultry, Other)...
$ 3450
Sepsis Treatment Comprehensive Study by Type (Antibiotics, Intravenous Fluids, Vasopressors), Application (Sepsis, Severe Sepsis, Septic Shock), Technology (Microbiology, Molecular Diagnostics, Immun...
$ 3350
Triazolam Comprehensive Study by Type (0.25mg, 0.125mg, 0.5 mg), (), Distribution Channel (Online, Offline), End User (Adults, Older Adults, Children) Players and Region - Global Market Outlook to 2...
$ 3500
Roxithromycin Comprehensive Study by Type (Roxithromycin Tablets, Roxithromycin Capsules, Roxithromycin Granules), Application (Acute pharyngitis, Tonsillitis, Sinusitis, Pneumonia, Others), Patient...
$ 3650